Covid 19 Clinical Trials

	Name (Synonyms)	Correlation
drug2198	Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] Wiki	0.38
drug2613	Usual Care plus Customized Referrals Wiki	0.38
drug2339	Standard therapy for AUD Wiki	0.38
drug344	Bicalutamide 150 Mg Oral Tablet Wiki	0.38
drug2199	Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] Wiki	0.38
drug569	Chlorpromazine Wiki	0.38
drug2698	Woebot Substance Use Disorder Wiki	0.38
drug1507	Mobile Enhanced Prevention Support Wiki	0.38
drug2342	Standard therapy for TUD Wiki	0.38
drug2340	Standard therapy for AUD plus Chess-based cognitive treatment Wiki	0.38
drug2336	Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment Wiki	0.38
drug337	Best available treatment Wiki	0.38
drug1189	Implementation Facilitation (IF) Wiki	0.38
drug2302	Standard Dissemination Practice Wiki	0.38
drug568	Chloroquine phosphate Wiki	0.22

Correlated MeSH Terms (7)

	Name (Synonyms)	Correlation
D000437	Alcoholism NIH	0.44
D012749	Sexually Transmitted Diseases NIH	0.38
D015231	Sexually Transmitted Diseases, Bacterial NIH	0.38
D016739	Behavior, Addictive NIH	0.38
D006526	Hepatitis C NIH	0.38
D004194	Disease NIH	0.14
D004630	Emergencies NIH	0.07

Correlated HPO Terms (1)

	Name (Synonyms)	Correlation
HP:0030858	Addictive behavior HPO	0.38

There are 7 clinical trials

Clinical Trials

1 Opioid Use Disorder in the Emergency Department: Clinical Trials Network-0069

The purpose of this study is to evaluate the impact of (1) Implementation Facilitation (IF) on rates of provision of Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) treatment with referral for ongoing medication-assisted treatment (MAT) and the (2) effectiveness of IF on patient engagement in formal addiction treatment at 30 days.

NCT03023930 Opioid Use Disorder Other: Standard Dissemination Practice Other: Implementation Facilitation (IF)

MeSH:Disease Emergencies Substance-Related Disorders

Primary Outcomes

Description: The primary implementation outcome will be evaluated assessing the rate of ED-initiated BUP therapy with referral for ongoing MAT over the 12 month period.

Measure: Implementation (Considered the Primary Outcome)

Time: 12 months

Description: The primary effectiveness outcome is defined as the rates of patient engagement in formal addiction treatment on the 30th day post enrollment.

Measure: Effectiveness

Time: 30 Days Post Enrollment

Secondary Outcomes

Description: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

Measure: Implementation: Fidelity

Time: Baseline Period (Baseline)

Description: Fidelity will be measured using a critical action checklist relating to the provision of ED-initiated BUP with referral for ongoing MAT in eligible patients.

Measure: Implementation: Fidelity

Time: IF Evaluation Period (18 months)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: Pre IF (Baseline)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: Post IF (6 months)

Description: ED provider readiness and preparedness ruler score to initiate BUP and provide referral for ongoing MAT

Measure: Implementation: ED provider Readiness and Preparedness Ruler Score

Time: post IF Evaluation Period (12 months)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Pre IF (Baseline)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Post IF (6 months)

Description: ED ORCA score relating to ED-initiated BUP with referral for ongoing MAT

Measure: Implementation: ED Organizational Readiness to Change Assessment (ORCA) Score

Time: Post IF Evaluation Period (12 months)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: Pre IF (Baseline)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: Post IF (6 months)

Description: Community opioid treatment provider/program readiness and preparedness ruler score to continue MAT for patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community Readiness and Preparedness Ruler Score

Time: post IF Evaluation Period (12 months)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: Pre IF (Baseline)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: Post IF (6 months)

Description: Community opioid treatment provider/program ORCA score relating to receiving patients with OUD who have received ED-initiated BUP

Measure: Implementation: Community ORCA Score

Time: post IF Evaluation Period (12 months)

Description: Self-reported days of illicit opioid use (past 7 days) as measured by Time-Line Follow-Back methods at 30 days

Measure: Effectiveness: Opioid Use

Time: 30 days post enrollment

Description: Overdose event (past 30 days) captured by participant self-report, state medical examiner records, National Death Index and review of medical records

Measure: Effectiveness: Overdose Event

Time: 30 days post enrollment

Description: HIV risk taking behaviors (past 30 days) as measured by HIV Risk Taking Behavior Scale

Measure: Effectiveness: HIV Risk

Time: 30 days post enrollment

Description: All Healthcare Service Utilization Inpatient and Outpatient

Measure: Effectiveness: Healthcare Service Utilization

Time: 30 days post enrollment

Description: Rates of illicit opioid negative urines

Measure: Effectiveness: Illicit Opioid Urine Toxicology

Time: 30 days post enrollment

2 Prevention Support for People Leaving Jail Study

This study will provide HIV prevention and related support services to men who have sex with men and transgender women who have substance use disorders and are either leaving jail or recently released from jail, living in a residential facility providing substance use services or supportive housing . The researchers will compare the utilization of HIV prevention and other support services between individuals who receive routine case management provided following enrollment to those who have access to GeoPassport, a global position service (GPS)-based mobile app, incentives, and peer mentor support.

NCT04036396 HIV Infections Sexually Transmitted Diseases, Bacterial Hepatitis C Substance Use Disorders Behavioral: Mobile Enhanced Prevention Support Behavioral: Usual Care plus Customized Referrals

MeSH:Sexually Transmitted Diseases Sexually Transmitted Diseases, Bacterial Hepatitis C Substance-Related Disorders

Primary Outcomes

Description: Defined as the participant identifying and completing an appointment with a primary care provider who is willing and able to prescribe HIV pre-exposure prophylaxis. Provide documentation of the appointment.

Measure: Number of participants establishing a primary care provider who can prescribe PrEP (pre-exposure prophylaxis)

Time: 9 months

Description: Defined as the participant completing the screening process for PrEP with an eligible provider or PrEP navigator. Provide documentation of the appointment.

Measure: Number of participants obtaining screening for PrEP

Time: 9 months

Description: Defined as the participant obtaining a prescription for PrEP, providing documentation, reporting taking the medication

Measure: Number of participants who initiate PrEP regimen

Time: 9 months

Description: Defined as the participant self-reporting taking prescribed PrEP at least 4 days per week over the prior 30 days

Measure: Number of participants who demonstrate minimal adherence to PrEP

Time: 30 days

Description: The participant will provide documentation of filled PrEP prescriptions for 3 or more months

Measure: Number of participants who remain on PrEP for at least 3 months.

Time: 3 months

Description: Defined as the participant self-reporting having obtained HIV testing every 3 months over the 12 month follow-up period

Measure: Number of participants who undergo a HIV test every 3 months

Time: 9 months

Description: Defined by the participant self-reporting having obtained testing for these 3 bacterial sexually transmitted diseases (STDs) every 6 months over the 12 month follow-up period

Measure: Number of participants who undergo a test for gonorrhea, syphilis, and chlamydia every 6 months

Time: 9 months

Description: Defined by the participant self-reporting having obtained at least one test for Hepatitis C

Measure: Number of participants who undergo a test for hepatitis C

Time: 9 months

Description: Defined by the participant self-report of completing initial recommended SUD appointments within 3 months of jail release, consistent with each participant's recommended American Society of Addiction Medicine (ASAM) level of care

Measure: Number of participants obtaining treatment for substance use disorders (SUDs) in the community

Time: 3 months

Description: Defined by the participant self-reporting remaining engaged in treatment (i.e., continuing to attend meetings, counseling or other treatment activities) as defined by the recommended ASAM level of care in the 3 months prior to each follow-up interview.

Measure: Number of participants who remain engaged in treatment for substance use disorders (SUDs) in the community,

Time: 3 months

Secondary Outcomes

Description: Self-report of whether or not participants received follow-up care and treatment for HIV, STD, and hepatitis C infections diagnosed during study follow-up (n=300)

Measure: Number of participants in each arm receiving care and treatment for newly diagnosed HIV or STD infections.

Time: 9 months

Description: Measure the comparative effectiveness of each intervention arm on reducing recidivism (n=300), quantified as the number of respondents who are reincarcerated and the total number of reincarcerations per arm over the study period.

Measure: Number of participants in each arm experiencing recidivism

Time: 9 months

Description: Describe the temporal distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).

Measure: Temporal service utilization patterns of intervention arm participants

Time: 9 months

Description: Report the geographic distribution of PrEP uptake and supportive social service utilization patterns of the participants in the MEPS intervention arm using data collected via the GeoPassport mobile app (n=150).

Measure: Geographic service utilization patterns of intervention arm participants

Time: 9 months

3 Investigating Neurobiological Mechanisms of Chess as an Add-On Treatment Against Substance Use Disorder

Neurobiological and neuropsychological approaches to investigate the potential mechanism of action of chess as an add-on therapy (chess based - cognitive remediation treatment, CB-CRT) to reduce cognitive deficits in individuals with alcohol use disorder (AUD).

NCT04057534 Substance Use Disorders Behavioral: Standard therapy for AUD plus Chess-based cognitive treatment Behavioral: Standard therapy for AUD Behavioral: Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment Behavioral: Standard therapy for TUD

MeSH:Substance-Related Disorders

Primary Outcomes

Description: fMRI cue-reactivity task (Vollstädt-Klein et al. 2010)

Measure: change in neural cue-reactivity

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: fMRI sequential reinforcement-based task (Huys et al. 2012)

Measure: change in sequential reinforcement-based neural mechanisms

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: fMRI stop-signal task (Whelan et al. 2012)

Measure: change in neural correlates of inhibition

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: self-report

Measure: substance use (alcohol consumption and tabacco use)

Time: 3 months follow-up after the end of treatment

Description: fMRI spatial working memory task (Vollstädt-Klein et al. 2010)

Measure: change in neural working memory processes

Time: 2 time points: before and after 6 weeks chess-based cognitive training

Description: working memory capacity measured by letter-number sequencing task of the [Wechsler Memory Scale (Kent 2013)]; raw values will be transformed to IQ-like scales (mean 100, SD 15); the higher the value, the higher the working memory capacity

Measure: Change in working memory capacity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: One Touch Stockings of Cambridge task from the Cambridge Automated Neuropsychological Test Automated Battery (Robbins et al. 1994)

Measure: Change in planning ability

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: Internal-External Set Shifting task from the Cambridge Automated Neuropsychological Test Automated Battery (Robbins et al. 1994)

Measure: Change in cognitive flexibility

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: impulsivity measured with BIS scale [Barratt impulsiveness scale (Patton et al. 1995)];range 15-60; total score will be used; high values represent high impulsivity

Measure: Change in impulsivity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [Iowa Gambling Task (Bechara et al. 1994)]

Measure: Change in decision-making

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [Reversal learning task (Vanes et al. 2014)]

Measure: Change in mental flexibility

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Description: [d2 Test of Attention (Brickenkamp 2002)].

Measure: Change in attentional capacity

Time: 3 time points: before and after 6 weeks SCP plus after 3 months

Secondary Outcomes

Description: [measured with fMRI]

Measure: change in functional connectivity within the salience network (SN) and executive control network (ECN)

Time: 2 time points: before and after 6 weeks therapy and chess-based cognitive training

4 Quality of Life and Addiction Among Hospital Night Workers - Descriptive Study of APHP Workers in Paris

The current context of the Covid-19 health crisis leads to an over-solicitation of health systems, with hospital staff in the front line. These personnel are undergoing high levels of stress, an alteration of their life rhythm, but also of their health status and quality of life at work. In addition, night work, through the disruption of circadian rhythms, has consequences on physical and mental health. The more frequent worsening of the condition of certain patients at night increases the burden and responsibilities of night staff. Increasing the use of psychoactive substances (SPAs) can become a solution for managing stress, work rhythms, sleep disorders and their consequences. This self-medication behaviour is not without risks, neither for staff nor for patients. The ALADDIN study is a project made up of 2 waves of questionnaires - one during and the other after the Covid "hospital" crisis - filled in by the hospital night staff of AP-HP. This project will assess the impact of the Covid-19 epidemic on the quality of work life, mental health disorders, post-traumatic stress and substance use of hospital night staff. The main objectives of this study is to evaluate the prevalence of psychoactive substance consumption among the night shift healthcare workers of the AP-HP and to describe the participants' quality of working life. Methods The study is prospective study using an online self-completed questionnaire. The questionnaire was elaborated on the basis of the validated scales ASSIST (Alcohol, Smoking, and Substance Involvement Screening Test), AUDIT-C (Alcohol Use Disorder Test, shortened version) and HAD (for anxiety and depression) and on qualitative interviews conducted among care staff working the night shift. The questionnaire will be completed at t0 (baseline) and 18 months after. This study will provide data on the consumption psychoactive substances by night hospital workers adn their quality of working life. It will also allow us to compare their consumption with the general population, and to describe the risk factors influencing the consumption.

NCT04291534 Health Services Research Quality of Life Addiction Substance-Related Disorders Health Personnel

MeSH:Substance-Related Disorders Behavior, Addictive

HPO:Addictive behavior

Primary Outcomes

Description: Prevalence in APHP health workers of psychoactive substance consumption during the Covid 19 outbreak

Measure: Substance use prevalence

Time: at T0 month : baseline

Description: Evaluation of the quality of working life during the Covid 19 outbreak using a validated scale

Measure: Quality of working life scale

Time: at T0 month : baseline

Secondary Outcomes

Description: Identify the preferences for intervention to improve the quality of life or change the addictive risk of night hospital staff at the APHP. Preferences for intervention methods and ranking of the least preferred.

Measure: Intervention preference

Time: at T0 month

Description: Describe the risk factors associated with the consumption of psychoactive substances (PAS). Logistic or fish linear regression depending on the type of variable taken into account.

Measure: Psychoactive substance consumption and associated factors

Time: at T0 month

Description: Evaluate the impact of substance use on quality of life at work Principal component analysis and classification to see if there are consumer groups for the night and / or day population. Method for taking into account missing, unused or invalid data

Measure: Impact of substance consumption on quality of life at work

Time: at T0 month

Description: Describe the risk factors associated with tobacco use among night hospital workers,

Measure: Risk factors associated with tobacco use

Time: at T0 month

Description: Evaluate the impact of sleep quality on the quality of working life and perceived health of night staff

Measure: Impact of sleep quality on quality of working life and perceived health

Time: at T0 month

Description: Describe the links between QWL and sleep, anxiety, depressive syndromes, and workplace upheaval.

Measure: Impact of anxiety and depressive symptoms on sleep and QWL.

Time: at T0 month

Description: Describe the links between anxiety/depressive syndromes and workplace disruption, sleep, and the Covid epidemic.

Measure: Impact of sleep and workplace upheaval on anxiety and depressives symptoms

Time: at T month

Description: Comparison between the baseline score and prevalences and the score and prevalences 18 months after

Measure: Modification of quality of working life score and psychoactive substances consumption prevalences

Time: T18 months

Description: Analysis of the relation between declared change and evolution of the quality of life score

Measure: Comparison of modification of quality of life score and declared quality of life modification after 18 month

Time: T18 months

5 Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE

The current containment linked to COVID-19 will have consequences for people suffering from addiction and there is a risk of overdoses when the containment ends. So the investigators hypothesize that this health crisis is an opportunity to develop risk reduction and access to care for vulnerable people who lives with an addiction. The main objective of this study is to describe the changes in the psychoactive substances consumption during the containment in people suffering from addiction. The secondary objectives are to describe the evolution at 1 month from the end of the containment of problematic consumption and the level of access to care of these users

NCT04343339 Addiction, Substance COVID-19

MeSH:Substance-Related Disorders Behavior, Addictive

HPO:Addictive behavior

Primary Outcomes

Description: measurement of the difference in drugs consumption caused by containment (delta)

Measure: Evolution of consumption

Time: 1 day

Description: measurement of the difference in drugs consumption caused by containment (delta)

Measure: Evolution of consumption

Time: 1 month after confinmant

Secondary Outcomes

Description: number of drug users referred to care (%)

Measure: health care access

Time: 1 day

Description: number of drug users referred to care (%)

Measure: health care access

Time: 1 month after confinmant

6 Isolated During COVID-19: Effects of COVID-19's Social Restrictions on Loneliness and Psychosocial Symptomatology

This study seeks to gather data and insight on epidemiologic trends of loneliness and other behaviors in the wake of the CDC recommended "social distancing" during the COVID-19 pandemic. The objective of this study is to use a cross-sectional survey to assess the impact of COVID-19's associated recommendations (social distancing, self-isolation, and self-quarantine) on loneliness and psychosocial symptomatology (depression, anxiety, substance abuse) on young adults (18-35 years old).

NCT04440098 Loneliness Depression Anxiety Alcohol Abuse Drug Abuse

MeSH:Alcoholism Substance-Related Disorders

Primary Outcomes

Description: University of California Los Angeles ( UCLA) Loneliness Scale is a 20-item self-report questionnaire that evaluates subjective feelings of loneliness and social isolation. Participants rate items on a 4-point Likert scale ranging from 1 (never) to 4 (often).Items are summed to create a score that can range from 20-80, higher scores being indicative of greater loneliness.

Measure: Loneliness as evaluated by the UCLA loneliness scale

Time: Day 1

Description: Alcohol Use Disorder Identification Test (AUDIT) is a 10-item self-reported questionnaire used to identify individuals whose alcohol consumption could be hazardous for their health. Participants rate items in a 5-point Likert scale, indicating amount (0 to 10 drinks or more), frequency (never to daily or almost daily), and indication of problems caused by alcohol (yes or no). Items were summed up to create a score that can range from 0 to 50. A score of 1 to 7 indicates low risk consumption, whereas a score of 8-15 suggests risky or hazardous drinking, a score of more than 15 is likely to indicate high-risk drinking and alcohol dependence.

Measure: Alcohol Use as evaluated by the AUDIT

Time: Day 1

Description: The Drug Abuse Screening Test (DAST-10) is a 10-item self-reported screening test that provides a quantitative index of the degree of consequences related to drug abuse. Participants rate items yes or no, positive responses corresponding to 1 point. Items are summed up to create a score that can range from 0-10. A score of 1-2 represents risky behaviors related to drugs, 3-5 represents moderate problems, 6-8 represents substantial problems, and 9-10 represents severe problems.

Measure: Drug Use as evaluated by the DAST-10

Time: Day 1

Description: The General Anxiety Disorder Scale (GAD- 7) is a 7- item self-reported screening tool that assess presence and severity of Generalized Anxiety Disorder. Participants rated frequency of problems in a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Items are summed up to create a score with scores of 5, 10, and 15 being the cut-off points for mild, moderate and severe anxiety, respectively.

Measure: Anxiety as evaluated by GAD-7

Time: Day 1

Description: The Center for Epidemiologic Studies Depression scale (CES-D-10) is a 10-item self-reported measure that assesses the frequency of symptoms of depression. Participants rate frequency of symptoms in a 4-point Likert scale from 0 (rare or none of the time) to 3 (most or almost all the time). Items are summed up to create a score that ranges from 0 to 30, with higher scores representing greater depressive symptoms. A score of 16 or more represents clinical depression.

Measure: Depression as assessed by CES-D-10

Time: Day 1

7 Woebot for Substance Use Disorders During COVID-19

The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.